London: AstraZeneca said on Thursday that preliminary data from a trial showed that its Covid-19 shot, Vaxzevria, generated an increase in antibodies against Omicron and other variants when given as a third booster dose.
The increased response, also against the Delta variant, was seen in a blood analysis of people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding it would submit this data to regulators worldwide given the urgent need for boosters. Lab studies conducted by the university last month already found a three-dose course of Vaxzevria boosted antibody levels in the blood against the rapidly spreading Omicron variant.